- Home
- LCTX vs GGZ Comparison
LCTX vs GGZ Comparison
Compare LCTX & GGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- GGZ
- Stock Information
- Founded
- LCTX 1990
- GGZ 2013
- Country
- LCTX United States
- GGZ United States
- Employees
- LCTX N/A
- GGZ N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- GGZ Investment Managers
- Sector
- LCTX Health Care
- GGZ Finance
- Exchange
- LCTX Nasdaq
- GGZ Nasdaq
- Market Cap
- LCTX 107.3M
- GGZ 105.1M
- IPO Year
- LCTX N/A
- GGZ N/A
- Fundamental
- Price
- LCTX $1.03
- GGZ $13.44
- Analyst Decision
- LCTX Strong Buy
- GGZ
- Analyst Count
- LCTX 5
- GGZ 0
- Target Price
- LCTX $4.20
- GGZ N/A
- AVG Volume (30 Days)
- LCTX 4.1M
- GGZ 12.8K
- Earning Date
- LCTX 08-07-2025
- GGZ 01-01-0001
- Dividend Yield
- LCTX N/A
- GGZ 5.39%
- EPS Growth
- LCTX N/A
- GGZ N/A
- EPS
- LCTX N/A
- GGZ 1.75
- Revenue
- LCTX $9,557,000.00
- GGZ N/A
- Revenue This Year
- LCTX N/A
- GGZ N/A
- Revenue Next Year
- LCTX $232.66
- GGZ N/A
- P/E Ratio
- LCTX N/A
- GGZ $6.79
- Revenue Growth
- LCTX 19.42
- GGZ N/A
- 52 Week Low
- LCTX $0.37
- GGZ $9.43
- 52 Week High
- LCTX $1.15
- GGZ $12.50
- Technical
- Relative Strength Index (RSI)
- LCTX 65.72
- GGZ 60.33
- Support Level
- LCTX $0.97
- GGZ $13.44
- Resistance Level
- LCTX $1.12
- GGZ $13.67
- Average True Range (ATR)
- LCTX 0.10
- GGZ 0.11
- MACD
- LCTX -0.00
- GGZ -0.01
- Stochastic Oscillator
- LCTX 81.48
- GGZ 67.65
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.